What type of study is this?

This is a Mixed-Methods study (also classified as: Quantitative Study).

September 23, 2025The Annual Review of Pharmacology and Toxicology

Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development

View Full Paper

Ask AI

Bookmark

Authors

AYAbdoulaye YalcouyéUniversité des Sciences, des Techniques et des Technologies de Bamako KEKevin EsohJohns Hopkins University AWAmbroise WonkamJohns Hopkins University

Discussion

Member takes

Implication

This analysis highlights the urgent need for inclusive pharmacogenomic studies in African populations, indicating the potential for improved drug therapies.

Key Points

Enhanced studies in African populations could significantly improve pharmacogenomics and drug development globally.
The exploration of genetic diversity in African populations is crucial for understanding drug-related toxicity and efficacy.
High-throughput organoid models and polygenic risk scores are vital methodologies to strengthen pharmacogenetic research.
The development of PCSK9 inhibitors illustrates the importance of studying African genetic diversity in drug discovery.

Cite This Study

Yalcouyé et al. (2025) studied this question.

synapsesocial.com/papers/68d4726431b076d99fa6b93e https://doi.org/10.1146/annurev-pharmtox-071724-014737

View Full Paper

Ask AI

Bookmark

Implication

This analysis highlights the urgent need for inclusive pharmacogenomic studies in African populations, indicating the potential for improved drug therapies.

Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development

Discussion

Member takes

Implication

Key Points

Cite This Study

Enhancing Large-Scale Pharmacogenetic Studies in African Populations for Clinical Care and Drug Development

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider